Zhifei Biological's HPV Vaccine Revenue Share Continues to Decline
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
According to public information, Zhifei Biological (SZ300122)'s HPV vaccine revenue share shows a significant downward trend, with specific data as follows [1][2][3]:
| Period | Proportion of HPV Vaccine-related Revenue | Remarks |
|---|---|---|
2023 |
Approximately 98.05% |
Agency product revenue was RMB 51.885 billion, accounting for 98.05% of total revenue |
2024 |
Approximately 94.61% |
Agency product revenue accounted for 94.61% of total revenue; total revenue was RMB 26.07 billion |
First Half of 2025 |
Approximately 88.84% |
Agency product revenue accounted for 88.84% of total revenue; agency revenue was RMB 4.37 billion |
The revenue share of HPV vaccines (agency business) dropped from approximately
This decline is mainly due to:
-
Saturated Market Demand: In 2024, the first-dose coverage rate of HPV vaccines among women aged 9-45 in China reached 27.43%, and the vaccination rate in core cities is approaching saturation [1]
-
Accelerated Domestic Substitution: In June 2025, Wantai Biological launched a domestic 9-valent HPV vaccine priced at only RMB 499 per dose, which is less than 40% of the price of imported products [2]
-
Significant Performance Decline: In 2024, revenue fell 50.74% year-on-year to RMB 26.07 billion, and agency revenue dropped 75.16% year-on-year in the first half of 2025 [2]
[1] Eastmoney.com - Zhifei Biological Research Report (https://pdf.dfcfw.com/pdf/H3_AP202405221634335869_1.pdf)
[2] Phoenix Net Finance - Zhifei Biological Expected to Report a Loss of RMB 10.7 Billion to 13.7 Billion in 2025 (https://finance.ifeng.com/c/8q2Jx0uCtCb)
[3] OFweek - Zhifei Biological with RMB 48 Billion in Revenue, Inventory Exceeds RMB 20 Billion (https://mp.ofweek.com/biotech/a156714070627)
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.